Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EXAI Stock Summary
In the News
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscienti.
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Federal Reserve's decision to stop raising rates and its suggestions that it will cut rates later this year.
Exscientia boss departs over relationships with employees
Nasdaq-listed Exscientia shares crashed by more than a fifth as the Oxford-based biotech fired its founder and chief executive over "inappropriate relationships" with two employees. In a statement, the AI-focused drug developer said that Andrew Hopkins's behaviour was inconsistent with “the company's standards and values”.
MoneyShow's Best Investment Ideas For 2024: Part 4
This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?
The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now
Exscientia hopes its AI tools will make it easier to discover new medicines. A few big pharma companies seem to think that it's on to something.
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet
The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EXAI Financial details
EXAI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.55 | 0.27 | 0.2 | |
Net income per share | 0 | 0 | -0.99 | -1.17 | -1.46 | |
Operating cash flow per share | 0 | 0 | -0.13 | -0.6 | -1.18 | |
Free cash flow per share | 0 | 0 | -0.33 | -0.82 | -1.44 | |
Cash per share | 0 | 0 | 11.27 | 6.01 | 3.73 | |
Book value per share | 0 | 0 | 11.37 | 4.74 | 3.65 | |
Tangible book value per share | 0 | 0 | 10.22 | 4.34 | 3.59 | |
Share holders equity per share | 0 | 0 | 11.37 | 4.74 | 3.65 | |
Interest debt per share | 0 | 0 | 0.14 | 0.14 | 0.04 | |
Market cap | 1677.39B | 1627.88B | 985.55M | 650.9M | 796.1M | |
Enterprise value | 1677.35B | 1627.81B | 430.24M | 56.81M | 489.46M | |
P/E ratio | -202.52K | -53.61K | -20 | -4.55 | -4.39 | |
Price to sales ratio | 140.48K | 123.5K | 35.95 | 19.78 | 31.9 | |
POCF ratio | 182.11K | -55.73K | -147.79 | -8.89 | -5.45 | |
PFCF ratio | 240.2K | -50.19K | -60.62 | -6.48 | -4.44 | |
P/B Ratio | 58.01K | 20.41K | 1.74 | 1.13 | 1.76 | |
PTB ratio | 58.01K | 20.41K | 1.74 | 1.13 | 1.76 | |
EV to sales | 140.47K | 123.49K | 15.69 | 1.73 | 19.61 | |
Enterprise value over EBITDA | -192.49K | -51.43K | -7.58 | -0.25 | -2.4 | |
EV to operating cash flow | 182.1K | -55.73K | -64.52 | -0.78 | -3.35 | |
EV to free cash flow | 240.2K | -50.19K | -26.46 | -0.57 | -2.73 | |
Earnings yield | 0 | 0 | -0.05 | -0.22 | -0.23 | |
Free cash flow yield | 0 | 0 | -0.02 | -0.15 | -0.23 | |
Debt to equity | 0.05 | 0.06 | 0.01 | 0.03 | 0.01 | |
Debt to assets | 0.03 | 0.04 | 0.01 | 0.02 | 0.01 | |
Net debt to EBITDA | 4.57 | 2.45 | 9.78 | 2.59 | 1.5 | |
Current ratio | 2.35 | 4.71 | 12.72 | 6.05 | 6.22 | |
Interest coverage | -148.04 | -260.55 | -244.61 | -433.94 | -172.24 | |
Income quality | -0.87 | 0.88 | 0.09 | 0.43 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.52 | 0.92 | 0.94 | 1.41 | 0 | |
Research and developement to revenue | 0.73 | 1.13 | 1.61 | 4.73 | 5.67 | |
Intangibles to total assets | 0.01 | 0 | 0.09 | 0.06 | 0.01 | |
Capex to operating cash flow | -0.24 | 0.11 | 1.44 | 0.37 | 0.23 | |
Capex to revenue | -0.19 | -0.24 | -0.35 | -0.83 | -1.33 | |
Capex to depreciation | -2.96 | -2.22 | -1.7 | -2.37 | -1.71 | |
Stock based compensation to revenue | 0.08 | 0.21 | 0.52 | 1.12 | 0 | |
Graham number | 0 | 0 | 15.9 | 11.18 | 10.96 | |
ROIC | -0.24 | -0.32 | -0.08 | -0.24 | -0.41 | |
Return on tangible assets | -0.15 | -0.29 | -0.08 | -0.19 | -0.28 | |
Graham Net | 0 | 0 | 10.12 | 4.63 | 2.41 | |
Working capital | 28.29M | 73.99M | 723.48M | 559.57M | 433.26M | |
Tangible asset value | 28.48M | 79.33M | 509.86M | 529.99M | 445.59M | |
Net current asset value | 23.84M | 67.78M | 711.33M | 464.18M | 318.63M | |
Invested capital | 0.05 | 0.06 | 0.01 | 0.03 | 0.01 | |
Average receivables | 0 | 6.92M | 14.09M | 36.42M | 48.45M | |
Average payables | 0 | 3.72M | 6.52M | 22.85M | 25.83M | |
Average inventory | 0 | 1.52M | 1.76M | 272.51K | 30.26K | |
Days sales outstanding | 226.21 | 178.46 | 289.36 | 566.98 | 669.79 | |
Days payables outstanding | 143.43 | 85.52 | 181.04 | 337.78 | 98.7 | |
Days of inventory on hand | -0.34 | 57.22 | 10.33 | 0.55 | 0 | |
Receivables turnover | 1.61 | 2.05 | 1.26 | 0.64 | 0.54 | |
Payables turnover | 2.54 | 4.27 | 2.02 | 1.08 | 3.7 | |
Inventory turnover | -1.08K | 6.38 | 35.33 | 664.36 | 53.44M | |
ROE | -0.29 | -0.38 | -0.09 | -0.25 | -0.4 | |
Capex per share | 0 | 0 | -0.19 | -0.22 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.06 | 0.07 | 0.05 | 0.02 | 0.07 | |
Net income per share | -0.32 | -0.38 | -0.31 | -0.29 | -0.25 | |
Operating cash flow per share | -0.64 | -0.47 | -0.35 | -0.33 | -0.27 | |
Free cash flow per share | -0.7 | -0.54 | -0.46 | -0.39 | -0.31 | |
Cash per share | 5.11 | 5.96 | 3.63 | 3.23 | 2.94 | |
Book value per share | 4.65 | 4.7 | 3.63 | 3.37 | 3.16 | |
Tangible book value per share | 4.28 | 4.31 | 3.32 | 3.08 | 2.87 | |
Share holders equity per share | 4.65 | 4.7 | 3.63 | 3.37 | 3.16 | |
Interest debt per share | 0.06 | 0.14 | 0.16 | 0.15 | 0.15 | |
Market cap | 901.7M | 655.4M | 527.37M | 580.75M | 465.55M | |
Enterprise value | 395.06M | 61.31M | 351.48M | 351.3M | 374.57M | |
P/E ratio | -5.69 | -3.48 | -3.5 | -4.04 | -3.73 | |
Price to sales ratio | 128.21 | 79.93 | 91.54 | 193.2 | 52.41 | |
POCF ratio | -11.54 | -11.26 | -12.15 | -14.07 | -13.63 | |
PFCF ratio | -10.56 | -9.81 | -9.39 | -12.13 | -12.19 | |
P/B Ratio | 1.58 | 1.13 | 1.18 | 1.39 | 1.18 | |
PTB ratio | 1.58 | 1.13 | 1.18 | 1.39 | 1.18 | |
EV to sales | 56.17 | 7.48 | 61.01 | 116.86 | 42.17 | |
Enterprise value over EBITDA | -7.95 | -1.31 | -9.21 | -9.16 | -11.63 | |
EV to operating cash flow | -5.05 | -1.05 | -8.1 | -8.51 | -10.96 | |
EV to free cash flow | -4.63 | -0.92 | -6.26 | -7.34 | -9.81 | |
Earnings yield | -0.04 | -0.07 | -0.07 | -0.06 | -0.07 | |
Free cash flow yield | -0.09 | -0.1 | -0.11 | -0.08 | -0.08 | |
Debt to equity | 0.01 | 0.03 | 0.04 | 0.04 | 0.05 | |
Debt to assets | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | |
Net debt to EBITDA | 10.19 | 12.72 | 4.61 | 5.98 | 2.82 | |
Current ratio | 7.55 | 6.05 | 7.03 | 6.88 | 6.67 | |
Interest coverage | -464.22 | -379.75 | -174.08 | -170.36 | -141.52 | |
Income quality | 2.01 | 0.87 | 1.01 | 0.97 | 1.02 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.64 | 1.21 | 1.89 | 3.87 | 1.25 | |
Research and developement to revenue | 5.84 | 5.24 | 5.8 | 10.49 | 3.57 | |
Intangibles to total assets | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | |
Capex to operating cash flow | 0.09 | 0.15 | 0.29 | 0.16 | 0.12 | |
Capex to revenue | -1.03 | -1.05 | -2.22 | -2.2 | -0.45 | |
Capex to depreciation | -2.98 | -2.22 | -4.07 | -1.81 | -0.92 | |
Stock based compensation to revenue | 1.42 | 1.27 | 1.21 | 2.27 | 0.72 | |
Graham number | 5.81 | 6.37 | 5 | 4.7 | 4.22 | |
ROIC | -0.07 | -0.08 | -0.08 | -0.09 | -0.08 | |
Return on tangible assets | -0.06 | -0.06 | -0.07 | -0.07 | -0.06 | |
Graham Net | 3.87 | 4.6 | 2.45 | 2.15 | 2.11 | |
Working capital | 576.52M | 559.57M | 425.79M | 389.45M | 376.57M | |
Tangible asset value | 524.9M | 529.99M | 409.27M | 380.61M | 357.16M | |
Net current asset value | 483.99M | 464.18M | 340.82M | 309.06M | 285.77M | |
Invested capital | 0.01 | 0.03 | 0.04 | 0.04 | 0.05 | |
Average receivables | 35.58M | 44.43M | 46.05M | 44.87M | 59.53M | |
Average payables | 20.02M | 28.42M | 26.14M | 12.75M | 10.37M | |
Average inventory | 204.74K | 138.57K | -20.13M | -43.8M | -23.65M | |
Days sales outstanding | 483.1 | 560.91 | 640.48 | 1.46K | 712.51 | |
Days payables outstanding | 172.33 | 291.14 | 160.44 | 149.67 | 137.68 | |
Days of inventory on hand | 1.9 | 0.47 | -429.08 | -678.97 | 0 | |
Receivables turnover | 0.19 | 0.16 | 0.14 | 0.06 | 0.13 | |
Payables turnover | 0.52 | 0.31 | 0.56 | 0.6 | 0.65 | |
Inventory turnover | 47.36 | 190.05 | -0.21 | -0.13 | 6.74M | |
ROE | -0.07 | -0.08 | -0.08 | -0.09 | -0.08 | |
Capex per share | -0.06 | -0.07 | -0.1 | -0.05 | -0.03 |
EXAI Frequently Asked Questions
What is Exscientia plc stock symbol ?
Exscientia plc is a GB stock and trading under the symbol EXAI
What is Exscientia plc stock quote today ?
Exscientia plc stock price is $5.71 today.
Is Exscientia plc stock public?
Yes, Exscientia plc is a publicly traded company.